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S362 Poster Session IIniche demonstrated exacerbated loss of ISC in IL-22 KO mice dur-
ing GVHD.
In summary, IL-22 was produced post-BMT by host ILC that
were eliminated during GVHD, and IL-22 deficiency increased
GVHD morbidity and mortality. While IL-22 deficiency did not
significantly alter the donor immune response, it did lead to in-
creased GVHD pathology, loss of epithelial integrity, and loss of
ISC. IL-22 is thus critical for protection of host epithelium during
GVHD. This may be exploited in the future to reduce clinical
GVHD without limiting the curative potential of the transplant.427
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Introduction: We have recently established an immunodeficient
NOD/SCID/IL2Rgcnull (NSG) mouse model that allows the reli-
able engraftment of primary human acute myeloid leukemia
(AML) blasts, particularly those with FLT3-ITD mutations. We
now use these mice as a platform to evaluate the graft-versus-leuke-
mia (GvL) effect of human leukemia-reactive T cells in vivo. To sys-
tematically optimize essential parameters for survival and effector
function of human T cells in NSG mice, large numbers of AML-re-
active cytotoxic T lymphocytes (CTL) were generated in vitro by
stimulation of healthy donor CD8+ T cells with FLT3-ITD+ AML
blasts in either singleHLA-class I-mismatched orHLA-matched sit-
uations.
Methods: 5x10e5 AML blasts were injected into 6-8 week-old irra-
diated (150cGy) NSG mice to achieve 1-5% AML engraftment in
bone marrow (BM) within 18 days (d) resembling minimal residual
disease. Subsequently, 5x10e6 alloreactive CD8+ CTL expanded
over 14, 21, 28, and 56 d in vitro were transfused into mice to inves-
tigate differences in homing, survival, and GvL reactivity in vivo.
Controls included AML-engrafted mice without CTL as well as
mice receiving CTL of irrelevant antiviral specificity. All mice re-
ceived human interleukin (IL)2, IL7-Fc and IL15 at time of T cell
injection. AML-reactivity was analyzed in kinetic studies 2 h, 24 h,
48 h and 7 d after CTL transfer.
Results: We observed complete eradication of patient-derived
FLT3-ITD+ AML blasts in BM, spleen and peripheral blood of
mice one week after transfer of single locus HLA-B mismatched
CTL that had been cultured for 14, 21, or 28 d, respectively. In con-
trast, control mice showed 25-61% (median 35%) leukemia infiltra-
tion in BM. Kinetic analysis demonstrated almost complete AML
remission as early as 48 h after T cell transfer. Ex vivo analysis of
CTL re-isolated from murine spleens 24 and 48 h after injection
showed persistent reactivity to AML blasts, but not to NSG-derived
murine dendritic cells. Interestingly, CTL expanded over 56 d in vi-
tro appeared less capable to eradicate AML in vivo. Results were re-
producible in 2 different donor-patient pairs and, moreover, are in
line with ongiong studies in HLA-matched systems.
Conclusion: We show herein that NSG mice engrafted with pri-
mary human AML blasts can be successfully treated with human al-
loreactive CTL. The model will be further optimized to serve as
a general platform for testing the GvL effect of T cell grafts before
adoptive transfer into humans.428
PRELIMINARY RESULTS OF A PHASE II TRIAL OF MONTELUKAST FOR THE
TREATMENT OF BRONCHIOLITIS OBLITERANS SYNDROME AFTER HSCT
Williams, K.M.1, Pavletic, S.Z.1, Hakim, F.T.1, Mitchell, S.A.2, Gea-
Banacloche, J.C.1, Comis, L.3, Cowen, E.W.4, Baird, K.5,
Shelhamer, J.H.6, Blacklock-Schuver, B.A.J.1, Avila, D.1,
Carpenter, A.1, Urban, A.1, Taylor, T.1, Zuchlinski, D.1,
Baruffaldi, J.1, Lee, S.7, Gress, R.E.1 1National Cancer Institute/NIH,
Bethesda, MD; 2National Cancer Institute/NIH, Bethesda, MD;3National Institutes of Health, Bethesda, MD; 4National Institutes of
Health, Bethesda, MD; 5National Cancer Institute/NIH, Bethesda,
MD; 6National Institutes of Health, Bethesda, MD; 7Fred Hutchinson
Cancer Research Center, Seattle, WA
Bronchiolitis obliterans syndrome (BOS) after allogeneic
HSCT is a deadly manifestation of cGVHD. Current treatments
are inferior and yield transient responses with published overall
survival of 44% at 2 years. Although the pathogenesis of BOS af-
ter HSCT is unknown, a similar disease, BOS after lung trans-
plant is associated with elevated leukotriene levels. We present
preliminary results from a prospective, open label, phase II trial
testing the efficacy of montelukast, a leukotriene inhibitor, for
the treatment of BOS after HSCT. BOS diagnostic criteria in-
cluded: FEV1\75%, FEV1/VC \ 0.7 or air trapping on CT
and RV.120% or RV/TLC.120% in the absence of infection
and presence of another cGVHD manifestation. Subjects had sta-
ble or declining FEV1 on stable or decreasing immunosuppres-
sion. Twenty patients have been enrolled. One withdrew prior
to treatment and one withdrew after study medication initiation;
16/20 patients have reached the primary endpoint (6 months) on
study medication (10 mg qhs). Study participants age ranged
from 15-64 years, 12/20 female, with baseline FEV1 from 24
to 73% predicted. All patients met criteria for response on the
clinical trial with less than 15% decline in FEV1 % predicted
at the primary endpoint. FEV1 increased 5-13% predicted in 5
participants, remained stable in 6 (change \5%), and declined
5-13% in 5. Comparison of patient pre-study FEV1 decline to
on-study FEV1 values was generated using the slope of FEV1
volume vs. days post-transplant. The difference in pre- and pri-
mary endpoint slope revealed: 14/16 improvement and 2/16 de-
cline. Six minute walk test demonstrated that 4/16 patients had
significant increases in walk distance that exceeded the minimally
important difference, 2 of which had declining FEV1%. 2/20 had
a significant decline in walk test accompanied by a decline in
FEV1% predicted. Of 10 patients eligible for the 2 year end-
point, 7/10 are alive with 2 patients with durable FEV1 improve-
ments from baseline (FEV1+ 6%, +14%), 2 stable (FEV1 0%,
+1%), 3 with decline from baseline (FEV1 -4%, -4%, -8%).
Montelukast was well-tolerated with only one grade II probable
attributable adverse event (insomnia) during the six-month collec-
tion period. These findings suggest that montelukast is a promis-
ing therapy for BOS after allogeneic HSCT.429
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Aim: The immunological parameters governing the presentation
pathways for allogeneic peptides to induce graft-versus-host disease
(GVHD) are unclear. This is critical for the development of clinical
therapies based on antigen presentation to control deleterious allor-
eactive responses.
Method and Result: We developed a GVHD model following
a bone marrow transplant (BMT) system whereby presentation
of a processed recipient peptide within MHC class II can be spa-
tially and temporally quantified. The presentation of peptide
within MHC class II by recipient antigen presenting cell (APC)
resulted in GVHD mortality within ten days. While donor
APC could induce lethal acute GVHD, recipient APC were
100-1000 times more potent. Antigen presentation by recipient
APC resulted in accumulation of antigen-specific T cells within
Poster Session II S363the gastrointestinal tract and severe histopathology. The specific
deletion of recipient dendritic cells surprisingly enhanced the ex-
pansion of donor alloantigen-specific T cells and accelerated
GVHD mortality due to a failure of activation-induced donor
T cell death. Consistent with this, the use of bone marrow-chi-
meric recipients demonstrated that professional, hematopoietic-
derived recipient APC in isolation were limited in their capacity
to induce GVHD. In contrast, non-hematopoietic recipient APC
in isolation induced universal GVHD mortality with high levels
of alloreactive donor T cell expansion and inflammatory cytokine
generation. Confocal imaging demonstrated that MHC class II is
highly expressed in recipient non-hematopoietic tissue within the
dermis and intestinal villi. Donor T cell activation (CD69) and
memory differentiation (CD62Llo/CD44hi) occurred in irradiated
recipients in an antigen-independent fashion and resulted in the
acquisition of a memory cell phenotype and Th1 differentiation
in lymph nodes. Within 3 days after BMT, these donor T cells
began entering the GI tract and interacted with MHC class II+
non-hematopoietic cells leading to lethal acute GVHD.
Conclusion: These data challenge current paradigms, demon-
strating that lethal acute GVHD can be induced by alloantigen
presented solely within MHC class II by non-hematopoietic re-
cipient APC.430
MEASUREMENT OF ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE
Treister, N.1, Lee, S.2, Chai, X.2, Kurland, B.2, Pidala, J.3, Palmer, J.4,
Flowers, M.2, Jagasia, M.5, Pavletic, S.6, Cutler, C.7 1Brigham and
Women’s Hospital, Boston, MA; 2Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 3Moffitt Cancer Center, Tampa, FL; 4Medical College
of Wisconsin, Milwaukee, WI; 5Vanderbilt Ingram Cancer Center, Nash-
ville, TN; 6National Cancer Institute, Center for Cancer Research, Be-
thesda, MD; 7Dana-Farber Cancer Institute, Boston, MA
Oral chronic graft-versus-host disease (cGVHD) is a serious com-
plication of allogeneic stem cell transplantation, and may be the pri-
mary site of disease activity. Scales and instruments recently
introduced to measure severity and response to therapy have not
been prospectively validated. The objective of this study was to de-
scribe the characteristics of oral cGVHD and determine the mea-
sures most sensitive to change.
Methods:Patients enrolled in the cGVHD Consortium with oral
involvement were included. Clinicians scored oral cGVHD ac-
cording to the 2005 NIH criteria for severity scoring (0-3) and
response (erythema, lichenoid changes, ulcers, mucoceles), and
patients completed measures. Other evaluated measures included
the esophageal response measure, Hopkins mouth score, and
weight. Clinicians and patients also rated change on an 8-point
scale, categorized as improved (1-3), stable (4-6), or worsened
(7-8).
Results: Of 458 participants with cGVHD, 72% (n 5 331) had oral
cGVHD involvement at enrollment and were followed for a median
of 13.6 months (2.0-38.5). Lichenoid change was the most common
objective finding (n5 293; 89%), and 25%of patients had only lichen-
oid involvement. Oral cGVHDwas not associated with global quality
of life as measured by the FACT-BMT or SF-36. At visits where
change could be assessed (n 5 501, 52% of follow-up visits), 51% of
clinicians and 56%patients reported improvement, withworsening re-
ported in 4-5% for both groups; agreement between clinician and pa-
tient perceived change was fair (weighted kappa5 0.41), but only 1%
of visits had highly discordant changes (improve vs. worse). Multivari-
able regression modeling suggested that the serial measurement
changes most predictive of perceived change by clinicians and patients
were the erythema and lichenoid scores, NIH severity score, clinician
assessed pain score and patient assessed Lee oral symptom score. Serial
change in erythema and lichenoid features showed synergy, with more
combined impact than each feature alone. Perceived changes in oral
cGVHDwere not associated with change in ulcers, mucoceles, esoph-
ageal scores or patient weight.
Conclusions: Oral involvement in cGVHD is common and associ-
ated with a wide range of signs and symptoms that generally improve
with time. Measurement of oral erythema and lichenoid changes,
pain and patient symptoms using 6 questionsmay adequately capture
the activity of oral cGVHD in clinical trials.431
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Following allogeneic bone marrow transplantation (allo BMT),
patients are at high risk for developing intestinal inflammation sec-
ondary to graft-versus-host disease (GVHD). While the impact of
the microbiota on GVHD is known to be significant, no consensus
exists between BMT centers regarding the optimal approach to tar-
get the flora.
We first examined in mouse models the effects of GVHD on gut
flora. While BMT alone produced surprisingly few changes in the
flora of mice, with GVHD we observed loss of overall diversity,
and in particular expansion of Lactobacillales and loss of Clostri-
diales. We studied the effects of eliminating Lactobacillales from
the flora of mice prior to BMT using antibiotics and observed aggra-
vation of GVHD, while re-introducing the predominant species of
Lactobacillus mediated significant protection resulting in improved
survival. These results frommurinemodels suggest thatGVHDpro-
duces unique changes in the flora, and that changes induced by anti-
biotics can aggravate GVHD.
We then characterized gut flora of eight patients undergoing allo
BMT during onset of intestinal inflammation due to GVHD, com-
pared to ten patients without GVHD. We again found patterns of
loss of diversity, expansion of Lactobacillales, and loss of Clostri-
diales, mirroring our findings in mice. We also identified increased
microbial chaos early following allo BMT as a potential risk factor
for subsequent GVHD. Together, these data increase our apprecia-
tion for reciprocal regulation of inflammation and flora in the intes-
tine, and suggest that flora manipulation may improve outcomes for
allo BMT recipients.Table. Summary of GVHD-induced changes in themicrobiota
Mice HumansNo GVHD GVHD No GVHD GVHDFlora diversity no change decreased no change decreased
Lactobacillales no change increased no change increased
Clostridiales no change decreased no change decreased432
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Introduction: Minor histocompatibility antigens located on the Y-
chromosome (HYminors) are known to play a pivotal role in alloge-
neic hematopoietic cell transplantation (HCT) with female donor
and male recipient. Only a few HYminors are known.We identified
a new HYminor using reverse immunology where candidate minors
first were predicted using bioinformatics and afterwards confirmed
with standard immune laboratory techniques.
Methods: Patient/donor pairs with female donors and male patients
were high resolution HLA typed. Candidate HY minor epitopes lo-
cated in genes only expressed on the Y chromosome were found us-
ing the HLA-pan restrictor (http://www.cbs.dtu.dk/services/
HLArestrictor). Post nonmyeloablative conditioning HCT PBMCs
from the patients were thawed, stimulated with these peptides and
tested for cytokine produktion (TNF-a and IFN-g) after restimula-
tion using flow cytometri. Approximately 140 peptides were synthe-
sized per patient/donor pair and the test for cytokine production was
carried out using a matrix system.When positive cytokine responses
were found, the optimal peptide and the HLA-restriction were de-
termined by affinity assays and tetramerstaining. Cytotoxity was
demonstrated by staining for CD107a.
Results: A strong cytokine response on an 11-mere peptide located
in the UTY gene was found in a patient transplanted for follicular
